Esranur Aydın, Clinical Cancer Molecular Biologist at Medicana Sağlık Grubu, shared a post on LinkedIn:
“Heading to Chicago for ASCO 2026!
Really excited to share that our work on the BRAF non-V600E and MAP2K1 landscape has been selected for a poster presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting!
We’ve been deep in real-world data from the WAYFIND-R registry, and it’s incredibly rewarding to bring these findings to such a global stage.
The field of molecularly targeted therapies is evolving at an amazing pace – and there’s no better place than ASCO to exchange ideas, challenge perspectives, and get inspired.
If you’ll be there, I’d love to connect – please feel free to stop by and say hi!
Session: Developmental Therapeutics.
Date: May 30, 2026.
Poster Board: 217.
Looking forward to great science, great conversations, and reconnecting with both familiar and new faces in Chicago. See you there!”
Other articles about ASCO on OncoDaily.